<DOC>
	<DOCNO>NCT01830010</DOCNO>
	<brief_summary>Two part study evaluate safety , tolerability , pharmacokinetics , efficacy ( Part 2 ) KRP203 patient undergo allogeneic hemopoietic stem cell transplant hematological malignancy</brief_summary>
	<brief_title>A Two-part Study Evaluate Safety , Tolerability , Pharmacokinetics , Efficacy KRP203 Patients Undergoing Stem Cell Transplant Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Patients age 18 65 year , inclusive Patients must hematological malignancy per standard medical practice require myeloablative conditioning ( include short term myeloablative reduce intensity conditioning ) follow allogeneic hematopoetic stem cell transplant Karnofsky Performance status â‰¥60 % . Suitable stem cell source available accord graft selection algorithm use Tcell replete peripheral stem cell graft source Resting heart rate 55 Significant cardiac disease ( arrhytmia , heart failure ) significant condition investigator opinion would make patient ineligible Previous allogeneic HSCT Any drug require compatible KRP203 ( e.g . betablockers antithymocyte globulin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>